Latest Insider Transactions at Biohaven Pharmaceutical Holding CO Ltd. (BHVN)
This section provides a real-time view of insider transactions for Biohaven Pharmaceutical Holding CO Ltd. (BHVN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Biohaven Pharmaceutical Holding Co Ltd. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Biohaven Pharmaceutical Holding Co Ltd.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 06
2021
|
Elyse Stock Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Indirect |
1,250
+36.37%
|
-
|
|
Jan 06
2021
|
Elyse Stock Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,747
-23.49%
|
$145,001
$83.38 P/Share
|
|
Jan 06
2021
|
Elyse Stock Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+33.52%
|
-
|
|
Jan 06
2021
|
William A Jones Jr CCO-Migraine & Common Disease |
SELL
Payment of exercise price or tax liability
|
Direct |
2,124
-22.96%
|
$176,292
$83.38 P/Share
|
|
Jan 06
2021
|
William A Jones Jr CCO-Migraine & Common Disease |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+35.09%
|
-
|
|
Jan 06
2021
|
John Tilton Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
492
-15.61%
|
$40,836
$83.38 P/Share
|
|
Jan 06
2021
|
John Tilton Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+28.4%
|
-
|
|
Nov 25
2020
|
Charles Conway Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,361
-15.75%
|
$122,490
$90.14 P/Share
|
|
Nov 25
2020
|
Charles Conway Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+25.78%
|
-
|
|
Nov 25
2020
|
Vlad Coric Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,965
-29.32%
|
$446,850
$90.14 P/Share
|
|
Nov 25
2020
|
Vlad Coric Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,950
+39.27%
|
-
|
|
Nov 25
2020
|
James Engelhart Strategic Advisor |
SELL
Payment of exercise price or tax liability
|
Direct |
1,678
-20.41%
|
$151,020
$90.14 P/Share
|
|
Nov 25
2020
|
James Engelhart Strategic Advisor |
BUY
Exercise of conversion of derivative security
|
Direct |
3,700
+31.04%
|
-
|
|
Nov 25
2020
|
Kimberly Gentile SVP, Clinical Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
1,701
-23.02%
|
$153,090
$90.14 P/Share
|
|
Nov 25
2020
|
Kimberly Gentile SVP, Clinical Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+33.67%
|
-
|
|
Nov 25
2020
|
William A Jones Jr CCO-Migraine & Common Disease |
SELL
Payment of exercise price or tax liability
|
Direct |
1,245
-26.18%
|
$112,050
$90.14 P/Share
|
|
Nov 25
2020
|
William A Jones Jr CCO-Migraine & Common Disease |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+38.68%
|
-
|
|
Nov 25
2020
|
Elyse Stock Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,531
-29.34%
|
$137,790
$90.14 P/Share
|
|
Nov 25
2020
|
Elyse Stock Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,375
+39.27%
|
-
|
|
Nov 25
2020
|
John Tilton Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
480
-23.76%
|
$43,200
$90.14 P/Share
|
|
Nov 25
2020
|
John Tilton Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+38.23%
|
-
|
|
Nov 23
2020
|
John W Childs |
BUY
Open market or private purchase
|
Direct |
5,000
+0.2%
|
$445,000
$89.55 P/Share
|
|
Nov 02
2020
|
William A Jones Jr CCO-Migraine & Common Disease |
SELL
Open market or private sale
|
Direct |
30,000
-59.02%
|
$2,280,000
$76.91 P/Share
|
|
Nov 02
2020
|
William A Jones Jr CCO-Migraine & Common Disease |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+48.58%
|
$1,500,000
$50.72 P/Share
|
|
Oct 23
2020
|
Gregory Bailey |
SELL
Open market or private sale
|
Direct |
10,403
-0.2%
|
$821,837
$79.42 P/Share
|
|
Oct 22
2020
|
Gregory Bailey |
SELL
Open market or private sale
|
Direct |
24,566
-0.48%
|
$1,940,714
$79.65 P/Share
|
|
Oct 19
2020
|
Gregory Bailey |
SELL
Open market or private sale
|
Direct |
4,554
-0.18%
|
$355,212
$78.98 P/Share
|
|
Oct 16
2020
|
Gregory Bailey |
SELL
Open market or private sale
|
Direct |
3,748
-0.14%
|
$292,344
$78.88 P/Share
|
|
Oct 12
2020
|
Gregory Bailey |
SELL
Open market or private sale
|
Direct |
6,729
-0.26%
|
$524,862
$78.87 P/Share
|
|
Oct 08
2020
|
Kimberly Gentile SVP, Clinical Operations |
SELL
Open market or private sale
|
Direct |
23,500
-43.94%
|
$1,786,000
$76.49 P/Share
|
|
Oct 08
2020
|
Kimberly Gentile SVP, Clinical Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
23,500
+46.41%
|
$211,500
$9.29 P/Share
|